Rheumatoid arthritis [RA] is an inflammatory arthritis that has affected nearly 1% of the world's total population. It is defined as the symmetrical polyarticular inflammation of the synovium, the small joints of one hand [MCP and PIP], the wrists and feet.
This inflammatory pain and stiffness can lead to progressive joint damage leading to malformations and lack of function. Related organ destruction also contributes to severe disability. In addition, chronic inflammation secondary to RA can also lead to higher chances of heart problems and changes in bone metabolism.
These newer drugs have proven to have better prospects for improving disease outcomes, but they also have noticed that they are accompanied by significant side effects that may pose long-term therapeutic challenges and difficulties for the preoperative stage.
Joint performance
Inflammation and continuous flattening of the synovial joint will be a hallmark of RA. Why your immune system is vulnerable to attack and destruction, and it is still unknown, but much progress has been made in figuring out how to produce it.
Inflammation of a person's synovial tissue includes interactions between macrophages, T lymphocytes and B lymphocytes, synovial fibroblasts, and other cells of an inflamed synovium, which may include mast cells, dendritic cells And plasma cells.
Bone manifestation
A RA patient is affected in a natural and systematic manner. According to the study, at local levels, the problem of stimulating osteoclasts leading to higher bone resorption is transmitted from inflammatory and fibroblast vascular cells.
Airway performance
It is expected that the occurrence of airway disease in RA will affect about 20-30% of the total patients. Performance may include circumflex arthritis, pulmonary fibrosis, and small airway disease, which are generally considered histopathologically as bronchiolitis obliterans, with impaired problems in lung function tests.
Pulmonary diseases are more common in seropositive, smog and long-term male RA patients.
Cardiovascular performance
The symptoms of patients affected by rheumatoid arthritis increased by 40% compared with the actual population after 20 years of asymptomatic. The possibility of increased mortality is usually associated with a higher incidence of heart disease.
A recent study showed that RA patients had a twice-fold higher incidence of cardiovascular events than the normal population, which is comparable to the potential risk of diabetic patients.
Drug selection for treating RA
DMARDs treatment
DMARDs [disease-modifying antirheumatic drugs] became one of the important treatments for RA disease in the 1970s. As a group, they have been shown to reduce inflammation and reduce the rate of radiological progression; however, the extent to which this often occurs is uneven.
The time period in which the DMARD begins is actually controversial, but the current consensus suggests that the overall outcome of the previous treatment, clinical improvement, and prevention of erosive disease is better.
The first 15 months of RA disease are critical to the initiation and increase of DMARD treatment in order to achieve acceptable results over the long term. A serious problem in treating patients with RA is because it is currently impossible to determine which patients will improve which medication.
Biological DMARDs
More and more drugs for specific immune system abnormalities, the so-called biological agent DMARD, have completely changed the RA disease.
This expanding multi-drug targeting has found that molecules play an important role in the pathology of RA. Due to cost and negative effects, it is generally recommended to use a bio-DMARD after the patient has not been treated with a single or combination of standard DMARDs.
Therefore, the treatment of RA has always been a key process in medical science, and there are many advanced drugs that can be used to reduce the effects of RA under medical observation.
Orignal From: New method for rheumatoid arthritis
No comments:
Post a Comment